Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2020

01-12-2020 | Premature Birth | Research article

First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases

Authors: Jilin Hu, Jinman Zhang, Guilin He, Shu Zhu, Xinhua Tang, Jie Su, Qian Li, Yamin Kong, Baosheng Zhu

Published in: BMC Pregnancy and Childbirth | Issue 1/2020

Login to get access

Abstract

Background

It is well known that second-trimester maternal serum alpha-fetoprotein (MS-AFP) is a predictor for adverse pregnancy outcomes (APOs), such as preterm birth, stillbirth, preeclampsia and small for gestational age (SGA). However, it is unknown whether first-trimester MS-AFP is also predictive of APOs.

Methods

We retrospectively reviewed the data on the first-trimester MS-AFP levels and pregnancy outcomes of 3325 singleton pregnant women. The cutoff value of 2.5 multiple of the median (MoM) was used to evaluate the risks of APOs regarding MS-AFP. The receiver operating characteristic (ROC) curves were used to evaluate the predictive efficiencies of MS-AFP to these disorders.

Results

A total of 181 pregnancies resulted in preterm birth, 32 in stillbirth, 81 in preeclampsia, and 362 in SGA. Compared to women with MS-AFP < 2.5MoM, those with MS-AFP ≥ 2.5MoM had increased risks (odds ratio, 95% confidence interval) of preterm birth (2.53, 1.65~3.88), preeclampsia (3.05, 1.71~5.43) and SGA (1.90, 1.34~2.69), and had an earlier distribution of gestational weeks at delivery (P = 0.004) and a lower distribution of neonatal birth weights (P = 0.000), but the actual between-group differences were minuscule. The areas under ROC curves were 0.572 (P = 0.001), 0.579 (P = 0.015) and 0.565 (P = 0.000) for preterm birth, preeclampsia and SGA, respectively. Subdivisions for the disorders did not obviously improve the performances of MS-AFP.

Conclusions

Elevated first-trimester MS-AFP is associated with increased risk of preterm birth, preeclampsia and SGA. However, the predictive efficiencies were low and it is not a good predictor for these APOs.
Literature
1.
go back to reference Lawn JE, Blencowe H, Waiswa P, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387:587–603.CrossRefPubMed Lawn JE, Blencowe H, Waiswa P, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387:587–603.CrossRefPubMed
2.
go back to reference Lawn JE, Blencowe H, Oza S, et al. Every newborn: progress, priorities, and potential beyond survival. Lancet. 2014;384:189–205.CrossRefPubMed Lawn JE, Blencowe H, Oza S, et al. Every newborn: progress, priorities, and potential beyond survival. Lancet. 2014;384:189–205.CrossRefPubMed
3.
go back to reference Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.CrossRefPubMed Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.CrossRefPubMed
4.
go back to reference ACOG Committee Opinion No. 743 summary: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132:254–6. ACOG Committee Opinion No. 743 summary: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132:254–6.
5.
go back to reference Wilson RD. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can. 2014;36:927–39.CrossRefPubMed Wilson RD. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can. 2014;36:927–39.CrossRefPubMed
6.
go back to reference Krause TG, Christens P, Wohlfahrt J, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome (1). Obstet Gynecol. 2001;97:277–82.PubMed Krause TG, Christens P, Wohlfahrt J, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome (1). Obstet Gynecol. 2001;97:277–82.PubMed
7.
go back to reference Smith GC, Wood AM, Pell JP, et al. Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome. N Engl J Med. 2004;351:978–86.CrossRefPubMed Smith GC, Wood AM, Pell JP, et al. Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome. N Engl J Med. 2004;351:978–86.CrossRefPubMed
8.
go back to reference Cohen JL, Smilen KE, Bianco AT, et al. Predictive value of combined serum biomarkers for adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;181:89–94.CrossRefPubMed Cohen JL, Smilen KE, Bianco AT, et al. Predictive value of combined serum biomarkers for adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;181:89–94.CrossRefPubMed
9.
go back to reference Puntachai P, Wanapirak C, Sirichotiyakul S, et al. Associations between pregnancy outcomes and unexplained high and low maternal serum alpha-fetoprotein levels. Arch Gynecol Obstet. 2015;292:81–5.CrossRefPubMed Puntachai P, Wanapirak C, Sirichotiyakul S, et al. Associations between pregnancy outcomes and unexplained high and low maternal serum alpha-fetoprotein levels. Arch Gynecol Obstet. 2015;292:81–5.CrossRefPubMed
10.
go back to reference Basbug D, Basbug A, Gulerman C. Is unexplained elevated maternal serum alpha-fetoprotein still important predictor for adverse pregnancy outcome? Ginekol Pol. 2017;88:325–30.CrossRefPubMed Basbug D, Basbug A, Gulerman C. Is unexplained elevated maternal serum alpha-fetoprotein still important predictor for adverse pregnancy outcome? Ginekol Pol. 2017;88:325–30.CrossRefPubMed
11.
go back to reference Yefet E, Kuzmin O, Schwartz N, Basson F, Nachum Z. Predictive value of second-trimester biomarkers and maternal features for adverse pregnancy outcomes. Fetal Diagn Ther. 2017;42:285–93.CrossRefPubMed Yefet E, Kuzmin O, Schwartz N, Basson F, Nachum Z. Predictive value of second-trimester biomarkers and maternal features for adverse pregnancy outcomes. Fetal Diagn Ther. 2017;42:285–93.CrossRefPubMed
12.
go back to reference Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–7.CrossRefPubMed Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–7.CrossRefPubMed
13.
go back to reference Poon LC, McIntyre HD, Hyett JA, da Fonseca EB, Hod M. The first-trimester of pregnancy - a window of opportunity for prediction and prevention of pregnancy complications and future life. Diabetes Res Clin Pract. 2018;145:20–30.CrossRefPubMed Poon LC, McIntyre HD, Hyett JA, da Fonseca EB, Hod M. The first-trimester of pregnancy - a window of opportunity for prediction and prevention of pregnancy complications and future life. Diabetes Res Clin Pract. 2018;145:20–30.CrossRefPubMed
14.
go back to reference Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8–15.CrossRefPubMed Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8–15.CrossRefPubMed
15.
go back to reference Morris RK, Bilagi A, Devani P, Kilby MD. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017;37:253–65.CrossRefPubMed Morris RK, Bilagi A, Devani P, Kilby MD. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017;37:253–65.CrossRefPubMed
16.
go back to reference Ormesher L, Johnstone ED, Shawkat E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens. 2018;14:234–9.CrossRefPubMed Ormesher L, Johnstone ED, Shawkat E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens. 2018;14:234–9.CrossRefPubMed
17.
go back to reference Rittenschober-Bohm J, Waldhoer T, Schulz SM, et al. Vaginal Ureaplasma parvum serovars and spontaneous preterm birth. Am J Obstet Gynecol. 2019;220:594.e1–9.CrossRef Rittenschober-Bohm J, Waldhoer T, Schulz SM, et al. Vaginal Ureaplasma parvum serovars and spontaneous preterm birth. Am J Obstet Gynecol. 2019;220:594.e1–9.CrossRef
18.
go back to reference ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol. 2009;113:748–61. ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol. 2009;113:748–61.
19.
go back to reference Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104.CrossRefPubMed Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104.CrossRefPubMed
20.
go back to reference Yan Z, Ma R, Jing W. Birth weight percentile in normal singleton pregnancy in Kunming region. Prog Obstet Gynecol. 2010;19:99–103. Yan Z, Ma R, Jing W. Birth weight percentile in normal singleton pregnancy in Kunming region. Prog Obstet Gynecol. 2010;19:99–103.
21.
go back to reference Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48:333–9.CrossRefPubMed Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48:333–9.CrossRefPubMed
22.
go back to reference Hu J, Zhang Y, Zhang J, et al. Pregnancy outcomes of women with elevated second-trimester maternal serum alpha-fetoprotein. Taiwan J Obstet Gynecol. 2020;59:73–8.CrossRefPubMed Hu J, Zhang Y, Zhang J, et al. Pregnancy outcomes of women with elevated second-trimester maternal serum alpha-fetoprotein. Taiwan J Obstet Gynecol. 2020;59:73–8.CrossRefPubMed
23.
go back to reference Bredaki FE, Matalliotakis M, Wright A, Wright D, Nicolaides KH. Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks’ gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:466–71.CrossRefPubMed Bredaki FE, Matalliotakis M, Wright A, Wright D, Nicolaides KH. Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks’ gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:466–71.CrossRefPubMed
24.
go back to reference Beta J, Bredaki FE, Rodriguez Calvo J, Akolekar R, Nicolaides KH. Maternal serum alpha-fetoprotein at 11-13 weeks’ gestation in spontaneous early preterm delivery. Fetal Diagn Ther. 2011;30:88–93.CrossRefPubMed Beta J, Bredaki FE, Rodriguez Calvo J, Akolekar R, Nicolaides KH. Maternal serum alpha-fetoprotein at 11-13 weeks’ gestation in spontaneous early preterm delivery. Fetal Diagn Ther. 2011;30:88–93.CrossRefPubMed
25.
go back to reference Brownbill P, Edwards D, Jones C, et al. Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. J Clin Invest. 1995;96:2220–6.CrossRefPubMedPubMedCentral Brownbill P, Edwards D, Jones C, et al. Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. J Clin Invest. 1995;96:2220–6.CrossRefPubMedPubMedCentral
26.
go back to reference Tian X, Zhu M, Du L, et al. Intrauterine inflammation increases materno-fetal transfer of gold nanoparticles in a size-dependent manner in murine pregnancy. Small. 2013;9:2432–9.CrossRefPubMed Tian X, Zhu M, Du L, et al. Intrauterine inflammation increases materno-fetal transfer of gold nanoparticles in a size-dependent manner in murine pregnancy. Small. 2013;9:2432–9.CrossRefPubMed
27.
go back to reference Hu J, Zhang J, Chan Y, Zhu B. A rat model of placental inflammation explains the unexplained elevated maternal serum alpha-fetoprotein associated with adverse pregnancy outcomes. J Obstet Gynaecol Res. 2019;45:1980–8.CrossRefPubMed Hu J, Zhang J, Chan Y, Zhu B. A rat model of placental inflammation explains the unexplained elevated maternal serum alpha-fetoprotein associated with adverse pregnancy outcomes. J Obstet Gynaecol Res. 2019;45:1980–8.CrossRefPubMed
28.
go back to reference Ilekis JV, Tsilou E, Fisher S, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an executive workshop summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol. 2016;215:S1–s46.CrossRefPubMedPubMedCentral Ilekis JV, Tsilou E, Fisher S, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an executive workshop summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol. 2016;215:S1–s46.CrossRefPubMedPubMedCentral
29.
go back to reference Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388:2629–41.CrossRefPubMed Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388:2629–41.CrossRefPubMed
30.
go back to reference Hughes AE, Sovio U, Gaccioli F, et al. The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome. Placenta. 2019;81:25–31.CrossRefPubMed Hughes AE, Sovio U, Gaccioli F, et al. The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome. Placenta. 2019;81:25–31.CrossRefPubMed
31.
go back to reference Umazume T, Yamada T, Morikawa M, et al. Occult fetomaternal hemorrhage in women with pathological placenta with respect to permeability. J Obstet Gynaecol Res. 2016;42:632–9.CrossRefPubMed Umazume T, Yamada T, Morikawa M, et al. Occult fetomaternal hemorrhage in women with pathological placenta with respect to permeability. J Obstet Gynaecol Res. 2016;42:632–9.CrossRefPubMed
32.
go back to reference Yue X, Sun Y, Zhong M, et al. Decreased expression of fibroblast growth factor 13 in early-onset preeclampsia is associated with the increased trophoblast permeability. Placenta. 2018;62:43–9.CrossRefPubMed Yue X, Sun Y, Zhong M, et al. Decreased expression of fibroblast growth factor 13 in early-onset preeclampsia is associated with the increased trophoblast permeability. Placenta. 2018;62:43–9.CrossRefPubMed
33.
go back to reference Jansen MW, Korver-Hakkennes K, van Leenen D, et al. Significantly higher number of fetal cells in the maternal circulation of women with pre-eclampsia. Prenat Diagn. 2001;21:1022–6.CrossRefPubMed Jansen MW, Korver-Hakkennes K, van Leenen D, et al. Significantly higher number of fetal cells in the maternal circulation of women with pre-eclampsia. Prenat Diagn. 2001;21:1022–6.CrossRefPubMed
34.
go back to reference Burton GJ, Jauniaux E. What is the placenta? Am J Obstet Gynecol. 2015;213:S6.e1 S6–8.CrossRef Burton GJ, Jauniaux E. What is the placenta? Am J Obstet Gynecol. 2015;213:S6.e1 S6–8.CrossRef
36.
go back to reference Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 2018;219:399.e1–6.CrossRef Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol. 2018;219:399.e1–6.CrossRef
37.
go back to reference Roberge S, Sibai B, McCaw-Binns A, Bujold E. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol. 2016;33:781–5.CrossRefPubMed Roberge S, Sibai B, McCaw-Binns A, Bujold E. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol. 2016;33:781–5.CrossRefPubMed
39.
go back to reference Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH. Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. Prenat Diagn. 2011;31:75–83.CrossRefPubMed Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH. Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. Prenat Diagn. 2011;31:75–83.CrossRefPubMed
40.
go back to reference Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH. First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther. 2012;31:154–61.CrossRefPubMed Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH. First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther. 2012;31:154–61.CrossRefPubMed
41.
go back to reference Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33:16–27.CrossRefPubMed Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33:16–27.CrossRefPubMed
42.
go back to reference Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH. Prediction of stillbirth from placental growth factor at 11-13 weeks. Ultrasound Obstet Gynecol. 2016;48:618–23.CrossRefPubMed Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH. Prediction of stillbirth from placental growth factor at 11-13 weeks. Ultrasound Obstet Gynecol. 2016;48:618–23.CrossRefPubMed
43.
go back to reference Hui PW, Tang MH, Lam YH, et al. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. Hum Reprod. 2003;18:572–5.CrossRefPubMed Hui PW, Tang MH, Lam YH, et al. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. Hum Reprod. 2003;18:572–5.CrossRefPubMed
44.
go back to reference Ombelet W, Martens G, Bruckers L. Pregnant after assisted reproduction: a risk pregnancy is born! 18-years perinatal outcome results from a population-based registry in Flanders. Belgium Facts Views Vis Obgyn. 2016;8:193–204.PubMed Ombelet W, Martens G, Bruckers L. Pregnant after assisted reproduction: a risk pregnancy is born! 18-years perinatal outcome results from a population-based registry in Flanders. Belgium Facts Views Vis Obgyn. 2016;8:193–204.PubMed
45.
go back to reference Riesche L, Bartolomei MS. Assisted reproductive technologies and the placenta: clinical, morphological, and molecular outcomes. Semin Reprod Med. 2018;36:240–8.CrossRefPubMed Riesche L, Bartolomei MS. Assisted reproductive technologies and the placenta: clinical, morphological, and molecular outcomes. Semin Reprod Med. 2018;36:240–8.CrossRefPubMed
46.
go back to reference Giguere Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361–75.CrossRefPubMed Giguere Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361–75.CrossRefPubMed
47.
go back to reference Liang J, Mu Y, Li X, et al. Relaxation of the one child policy and trends in caesarean section rates and birth outcomes in China between 2012 and 2016: observational study of nearly seven million health facility births. BMJ. 2018;360:k817.CrossRefPubMedPubMedCentral Liang J, Mu Y, Li X, et al. Relaxation of the one child policy and trends in caesarean section rates and birth outcomes in China between 2012 and 2016: observational study of nearly seven million health facility births. BMJ. 2018;360:k817.CrossRefPubMedPubMedCentral
Metadata
Title
First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases
Authors
Jilin Hu
Jinman Zhang
Guilin He
Shu Zhu
Xinhua Tang
Jie Su
Qian Li
Yamin Kong
Baosheng Zhu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2020
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-020-2789-2

Other articles of this Issue 1/2020

BMC Pregnancy and Childbirth 1/2020 Go to the issue